ANAPTYSBIO, INC (ANAB) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Mar 03, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for ANAPTYSBIO, INC?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ANAPTYSBIO, INC's filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
+9.18%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does ANAPTYSBIO, INC actually do?
Answer:
AnaptysBio is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes three wholly owned antibody candidates: rosnilimab for rheumatoid arthritis, ANB033 for celiac disease and eosinophilic esophagitis, and ANB101 for autoimmune and inflammatory diseases. AnaptysBio has also out-licensed therapeutic antibodies, including a PD-1 antagonist (Jemperli) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals, from which it recognizes milestone and royalty revenue. The company announced plans in September 2025 to separate into two independent, publicly traded companies: one focused on managing financial collaborations and the other on clinical-stage biotechnology development.
Question:
What are ANAPTYSBIO, INC's revenue drivers?
Answer:
Revenue is primarily generated from milestone and royalty payments from collaborations, notably with GSK for Jemperli and with Vanda Pharmaceuticals for imsidolimab, as well as license and transition services revenue from the Vanda collaboration.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required